



Corporation with a Board of Directors (*Société Anonyme à Conseil d'Administration*)

Share capital : 21,610,998.20 euros

Registered office: 49, boulevard du général Martial Valin - 75015 Paris

RCS Paris 410 910 095

DOCUMENTS RELATED TO
THE GENERAL MEETING OF SHAREHOLDERS
APRIL 9, 2025

Translation for information purposes only

This document is a free translation (the "Translation") of Valerio Therapeutics' "ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 9 AVRIL 2025 - BROCHURE DE CONVOCATION", dated March 19, 2025. This Translation is provided for convenience and information purposes only. In the event of any ambiguity or conflict between the statements or other items contained herein and the corresponding statements in the French language "ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 9 AVRIL 2025 - BROCHURE DE CONVOCATION", the "ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES DU 9 AVRIL 2025 - BROCHURE DE CONVOCATION" shall prevail.

March 19, 2025

Madam, Sir,

Shareholders are hereby informed that they are invited to attend the Ordinary and Extraordinary General Meeting of Shareholders to be held on April 9, 2025 at 2 p.m. CET, **at the Company's registered office, 49 boulevard du Général Martial Valin, 75015 Paris.**

Enclosed are the following documents:

- Agenda;
- Text of the resolutions;
- Business Overview;
- Terms of participation in the general meeting;
- Request for the sending of additional documents.

AGENDA

Agenda for the Ordinary General Meeting

- First resolution: Dismissal of a member of the Board of Directors (Shefali Agarwal)
- Second resolution: Ratification of the co-optation of a member of the Board of Directors (*Jacques Mallet*)
- Third resolution: Ratification of the co-optation of a member of the Board of Directors (*Antoine Barouky*)

Agenda for the Extraordinary General Meeting

- Fourth resolution: Division of the par value of the Company's shares
- Fifth resolution: Amendment of Article 14 of the Company's Articles of Association

Agenda for the Ordinary and Extraordinary General Meetings

- Sixth resolution: Powers to carry out formalities

TEXT OF THE RESOLUTIONS

Agenda for the Ordinary General Meeting

First resolution

Dismissal of a member of the Board of Directors (Shefali Agarwal)

The General Meeting, voting under the quorum and majority conditions required for ordinary general meetings,

resolves to terminate, with immediate effect, the appointment of Mrs Shefali Agarwal as a Director of the Company.

Second resolution

Ratification of the co-optation of a member of the Board of Directors (Jacques Mallet)

The General Meeting, voting on the quorum and majority conditions for Ordinary General Meetings, resolves to ratify the co-optation of Mr Jacques Mallet as a Director of the Company for the remainder of the term of office of GammaX Corporate Advisory, which has resigned, i.e. until the Annual General Meeting to be held in 2025 to approve the financial statements for the year ended 31 December 2024.

Third resolution

Ratification of the co-optation of a member of the Board of Directors (Antoine Barouky)

The General Meeting, voting on the quorum and majority conditions for Ordinary General Meetings, resolves to ratify the co-optation of Mr Antoine Barouky as a Director of the Company for the remainder of the term of office of Mr Khalil Barrage, which has resigned, i.e. until the Annual General Meeting to be held in 2025 to approve the financial statements for the year ended 31 December 2024.

Agenda for the Extraordinary General Meeting

Fourth resolution

Division of the par value of the Company's shares

The General Meeting, voting on the quorum and majority conditions for Extraordinary General Meetings, having reviewed the Directors' Report, resolves as follows:

- to divide the par value of the Company's shares by fourteen (14) to reduce it from 0.14 euro per share to 0.01 euro per share and correlatively that the number of existing shares in the Company will be multiplied by fourteen (14), so that the total amount of the Company's capital remains unchanged following this operation and the number of shares making up the share capital is increased from 154, 364,273 shares (each with a par value of 0.14 euro) to 2,161,099,820 shares (each with a par value of 0.01 euro);
- that the share split has no effect on the rights attached to the Company's shares as set out in the Company's Articles of Association, as the new shares will retain the same rights as the existing shares;
- that the division of the share capital into shares with a par value of 0.01 euro will give rise to the exchange of fourteen (14) new shares with a par value of 0.01 euro for 1 old share with a par value of 0.14 euro;

- that each share with a par value of 0.14 euro will automatically be replaced by fourteen (14) shares with a par value of 0.01 euro, with no change in the existing relationship between the Company and its shareholders as a result of this exchange;
- that the costs relating to the share split will be borne by the Company and that the transaction will therefore be carried out without any costs or formalities for shareholders,

grants full powers to the Company's Board of Directors, with the option of sub-delegation under the conditions laid down by law and regulations, to:

- set the effective date of the share split, which must take place before 31 December 2025;
- exchange the new shares for existing shares, issue the new shares and cancel the existing shares accordingly;
- amend the Company's Articles of Association to reflect the fourteen-for-one share split;
- to make any adjustments required as a result of this share split; and
- in general, to take all necessary measures, sign all deeds and documents, make all declarations and carry out all formalities to ensure the completion of the share split.

Fifth resolution

Amendment of Article 14 of the Company's Articles of Association

The General Meeting, voting on the quorum and majority conditions for Extraordinary General Meetings, having reviewed the Directors' Report and the draft amended Articles of Association, resolves:

- Regarding the attendance at meetings of the Board of Directors:
 - o to align the third paragraph of Article 14 “Board of Directors - Powers” of the Company's Articles of Association with the provisions of Article L.22-10-3-1 of the French Commercial Code, as amended by Act 2024-537 of June 13, 2024 (the “Attractiveness” Act); and
 - o to amend the third paragraph of Article 14 “Board of Directors - Powers” of the Company's Articles of Association accordingly, with the rest of the article remaining unchanged.

Current version	Proposed new version
<p>[...]</p> <p>The Board of Directors may only validly deliberate if at least half of its members are present. The internal regulations may stipulate that, for the purposes of calculating quorum and majority, directors who take part in the meeting by videoconference or telecommunication are deemed to be present, within the limits and under the conditions laid down by the laws and regulations in force. These videoconferencing and telecommunication procedures may not be used :</p>	<p>[...]</p> <p>The Board of Directors may only validly deliberate if at least half of its members are present. For the purposes of calculating quorum and majority, directors who take part in the meeting by means of telecommunication are deemed to be present, within the limits and under the conditions laid down by the laws and regulations in force.</p> <p>[...]</p>

<p>- for the preparation of the annual and consolidated financial statements ;</p> <p>- for the appointment and dismissal of the Chairman, Chief Executive Officer and Chief Operating Officers.</p> <p>[...]</p>	
---	--

- Regarding Directors' votes by written consultation:
 - o to bring the eleventh paragraph of Article 14 of the Company's Article of Association into line with the provisions of Article L. 225-37, paragraph 3 of the French Commercial Code, as amended by Act 2024-537 of June 13, 2024, known as the “Attractiveness” Act; and
 - o to amend the eleventh paragraph of Article 14 “Board of Directors - Powers” of the Company's Article of Association accordingly and as follows, with the rest of the article remaining unchanged.

Current version	Proposed new version
<p>[...]</p> <p>The Board of Directors may also take the following decisions by written consultation of the directors, which fall within the Board's specific powers:</p> <ul style="list-style-type: none"> - provisional appointment of Board members, in accordance with article L. 225-24 of the French Commercial Code, - authorization of securities, endorsements and guarantees as provided for in the last paragraph of article L. 225-35 of the French Commercial Code, - decision to amend the bylaws to bring them into line with legal and regulatory provisions, pursuant to a delegation of powers granted by the Extraordinary Shareholders' Meeting in accordance with the second paragraph of Article L. 225-36 of the French Commercial Code, - convening shareholders' meetings, and - transfer of the registered office to the same <i>département</i>. <p>When the decision is taken by written consultation, the text of the proposed resolutions, together with a ballot paper, is sent by the Chairman to each member of the Board of Directors by electronic means (with acknowledgement of receipt).</p> <p>Directors have a period of three (3) business days following receipt of the text of the proposed resolutions and the voting form to complete and return the voting form, dated and signed, to the Chairman by electronic means (with acknowledgement of receipt), ticking a single box for each resolution corresponding to the meaning</p>	<p>[...]</p> <p><u>Decisions of the Board of Directors may also be taken by written consultation of its members.</u></p> <p>When the decision is taken by written consultation, the text of the proposed resolutions together with a ballot paper is sent by the Chairman to each member of the Board of Directors by electronic means (with acknowledgement of receipt).</p> <p>Directors have a period of three (3) business days following receipt of the text of the proposed resolutions and the voting form in which to complete and return to the Chairman by electronic means (with acknowledgement of receipt) the voting form, dated and signed, ticking for each resolution a single box corresponding to the meaning of their vote.</p> <p><u>Any member of the Board has the same period of three (3) business days to object to the use of written consultation. In the event of opposition, the Chairman immediately informs the other members and convenes a meeting of the Board of Directors to rule on the decision(s) concerned.</u></p> <p>If none or more than one box has been ticked for the same resolution, the vote will be null and void and will not be taken into account when calculating the majority.</p> <p>Any director failing to reply within the above time limit will be deemed absent, and his or her vote will therefore not be taken into account in calculating quorum and majority.</p> <p>During the response period, any director may request further explanations from the initiator of the</p>

<p>of their vote.</p> <p>If none or more than one box has been ticked for the same resolution, the vote will be null and void and will not be taken into account when calculating the majority.</p> <p>Any Director who fails to reply within the above time limit will be deemed absent, and his or her vote will therefore not be taken into account for the purposes of calculating quorum and majority.</p> <p>During the response period, any director may request further explanations from the initiator of the consultation.</p> <p>Within five (5) business days of receipt of the last ballot paper, the Chairman will draw up and date the minutes of the deliberations, to which the ballot papers will be appended and which will be signed by the Chairman and a director who took part in the written consultation.</p> <p>Copies or extracts of Board resolutions are validly certified by the Chairman of the Board, the Chief Executive Officer, a Managing Director, the Managing Director temporarily acting as Chairman, or an authorized representative.</p> <p>[...]</p>	<p>consultation.</p> <p>Within five (5) business days of receipt of the last ballot, the Chairman will draw up and date the minutes of the deliberations, to which the ballots will be appended and which will be signed by the Chairman and a director who took part in the written consultation.</p> <p>Copies or extracts of Board resolutions are validly certified by the Chairman of the Board, the Chief Executive Officer, a Managing Director, the Managing Director temporarily acting as Chairman, or an authorized representative.</p> <p>[...]</p>
---	---

- Regarding the power of the Board of Directors to bring the bylaws into line with legislative and regulatory provisions:
 - o bring Article 14 of the Company's bylaws into line with the provisions of Article L.225-36 of the French Commercial Code, as amended by Act 2024-537 of June 13, 2024, known as the “Attractiveness” Act; and
 - o add the following paragraph at the end of Article 14 “Board of Directors - Powers” of the Company's Article of Association.

Current version	Proposed new version
N/A	In accordance with applicable legal provisions, the Board of Directors may make the necessary amendments to the bylaws to bring them into line with legislative and regulatory provisions, subject to ratification of such amendments by the next Extraordinary General Meeting.

Agenda for the Ordinary and Extraordinary General Meeting

Sixth resolution

Powers to carry out formalities

The General Meeting, voting under the quorum and majority conditions required for ordinary and extraordinary general meetings,

grants full powers to the bearer of an original, copy or extract of the present document to carry out all publication and filing formalities required by current legislation.

BUSINESS OVERVIEW IN 2024

Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing innovative drug candidates using two proprietary platforms: the PlatON platform and its unique DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The company strives to move innovative or breakthrough compounds from early translational research to clinical proof-of-concept, a value-creating inflection point attractive to potential partners.

Valerio Therapeutics is listed on Euronext Growth in Paris.

The Company's portfolio includes :

- **platON** is Valerio Therapeutics' proprietary chemical platform of DNA decoy therapies, generating innovative new compounds and expanding the company's product portfolio.
- **AsiDNA**, platON's first compound, is a highly differentiated first-in-class clinical-stage candidate in the field of DNA damage response (DDR) applied to oncology. Its DNA decoy therapeutic mechanism acting upstream of multiple DDR pathways translates into distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors, and strong synergy with tumor DNA-damaging agents such as radiotherapy and chemotherapy. Clinical development of AsiDNA has been halted in order to redirect research and development efforts on next-generation drug candidates from the two PlatON and V-Body platforms.
- **VIO-01 (formerly OX425)**, the second platON compound, is a novel pan-DDR decoy with high anti-tumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. In 2024, VIO-01 underwent its first phase 1 clinical development trial in the USA.
- **DecoyTAC** : the 3rd generation platON platform, exploiting the unique mode of action of DNA decoy therapies coupled to targeted protein degradation (PROTAC). This evolution extends the activity of the platON platform beyond DNA repair by targeting other proteins such as transcription factors, in oncology and outside oncology for other diseases such as inflammatory and muscular diseases. In 2024, a first proof-of-concept was generated by targeting the c-myc oncoprotein.
- **Plateforme V-bdoy** : the acquisition of Emglev Therapeutics (owned by Valour Bio, a subsidiary of Valerio Therapeutics) has enabled us to exploit phage-display technology to produce single-domain antibodies, known as V-bodies, from proprietary synthetic libraries. These V-bodies differ from traditional antibodies in that they are considerably smaller in size, around one-tenth that of conventional antibodies. This size advantage enables them to penetrate tissues more rapidly and reach targets that are generally difficult to access, while retaining the binding and/or neutralizing functions of a full antibody.

In addition, Valour Bio's proprietary libraries are humanized or fully human, which means they have been designed to reduce the potential for immunogenicity and toxicity. This humanization process improves their compatibility with the human immune system, which could make them more tolerable as therapeutic agents for patients.

The versatility of V-bodies enables them to target a wide range of antigens, broadening their therapeutic applicability. Single-domain antibodies (Sd-Abs) have demonstrated strong potential in a variety of pathologies, including autoimmune diseases, inflammatory conditions and cancer. Their ability to bind efficiently to a variety of targets makes them valuable tools for the development of antibody-based therapies for the most complex diseases.

V-bodies can be used in several therapeutic formats, such as bispecific T-cell “engagers” (BiTEs), antibody-drug conjugates (ADCs) and chimeric antigen receptors (CAR-Ts) grafted into T cells. Antibody-drug conjugates are particularly noteworthy, as they can deliver a variety of payloads, including radioisotopes, chemotherapeutic agents, small molecules or oligonucleotides.

This diversity of payloads broadens potential applications for different patient populations, making V-bodies a promising platform for biomedicine.

In addition, V-bodies can potentially be administered by different routes, such as subcutaneous, inhaled, oral or intravenous, offering a significant improvement over traditional antibodies which typically require intravenous administration.

Overall, Valour Bio's approach with V-bodies represents a major advance in the field of antibody-based therapies, providing potential solutions to the critical limitations of conventional antibodies.

→ Optimizing the PlatON platform with V-bodies:

The main challenges faced by DNA lures on the PlatON platform are their short half-life and specific delivery. Combining the V-body platform with the PlatON platform will leverage these two innovations by:

- **Extending half-life** thanks to an anti-albumin V-body conjugated to DNA lures
- **Increasing specificity** by using V-bodies targeting tissue-specific receptors for delivery, and conjugated to DNA lures.

The Company is convinced of the significant therapeutic potential of these technologies and the disruptive innovation they represent, which could pave the way for a new paradigm in cancer treatment.

1. R&D PROGRAMS

1.1. VIO-01

VIO-01, formerly OX425, is a Pan-DDR DNA decoy targeting multiple proteins and repair pathways, and represents the most optimal drug candidate selected to enter preclinical development. VIO-01 traps multiple DDR proteins inhibiting different DNA repair pathways. VIO-01 reaches the nucleus and acts as a decoy for several DNA repair enzymes. It has enhanced nuclease resistance and plasma stability.

VIO-01 has undergone advanced preclinical development enabling IND in 2023, with the completion of regulatory toxicology and ADME/PK studies. This package enabled the IND to be submitted to the FDA (Food and Drug Administration, the US regulatory agency), followed by approval to launch the first human clinical trial.

NEXT Oncology San Antonio, the first site of the Phase 1/2 study (VIO-01-101) for VIO-01, was activated and the first patient was treated in January 2024. To date, VIO-01 has been evaluated in **six patients at two different doses**, with an encouraging safety profile.

1.2. 3RD GENERATION OF platON™ PLATFORM

Valerio Therapeutics has continued to optimize the PlaTON™ platform to develop more potent actives coupled with innovative technologies, with the aim of combining the PlaTON™ platform's DNA decoys with the targeted protein degradation strategy offered by PROTACs (PROteolysis-TARgeting Chimeras) technology. PROTAC technology and other tumor-specific targeting options could constitute a new class of heterobifunctional molecules capable of selectively degrading target proteins in cells. This approach offers several advantages over other molecules involved in modulating the DNA damage response, such as enhanced selectivity and reduced toxicity. This specific strategy consists in generating DecoyTACs combining our vectorized DNA decoy molecules capable of efficiently penetrating cells with a + E3 binding ligand promoting the complete degradation of target proteins, thus presenting a novel mechanism of action.

Exploring the convergence of PROTACs and DNA Decoys aims not only to propose new therapeutic modalities against DDR proteins, but also against hard-to-target transcription factor proteins. A first proof of concept has been demonstrated by targeting the cMYC oncoprotein. Thanks to these efforts,

the Company is striving to advance the field of drug development and contribute to the treatment of patients suffering from pathologies with a real therapeutic need.

1.3. NEW V-BODY PLATFORM

Valour Bio's platform will enable the diversification and expansion of the company's portfolio towards other targets in oncology, as well as outside oncology, notably in autoimmune, inflammatory and rare genetic diseases. The assets generated by the PlatON platform (DNA decoys), the V-body platform (bispecifics, ADCs, CAR-T) or both combined (V-body-oligonucleotide conjugates) will revolutionize our approach to these diseases, and add value to the company by attracting different investors and facilitating future fundraising.

The last quarter of 2024 saw the internalization of the various expertises and technologies associated with this new platform, and the first proof-of-concept experiments.

2. EVOLUTION OF THE R&D PORTFOLIO

Developments compared with the portfolio presented in the 2023 annual report are as follows:

- Phase 1/2 of the VIO-01 clinical trial in the United States has begun, with the recruitment of six patients in 2024.
- First proofs of concept with DecoyTAC technology (3rd generation platON platform).
- Internalization of the new V-body platform

3. FUNDING

On April 30, 2024, Valerio Therapeutics received a €5 million financing commitment from its main shareholders, Artal and Financière de la Montagne. This commitment was realized in the form of a shareholders' current account in May 2024, providing the Company with a cash horizon to the end of 2024.

Part of this financing was used by Valerio Therapeutics to complete the acquisition of Emglev Therapeutics, for 2.5 million euros (part of which was paid in shares). The acquisition was made through its subsidiary Valour Bio.

The remainder of the financing was used to settle Valerio Therapeutics' ongoing operations and the development of the new Emglev platform.

At the end of 2024, a reduction in operating expenses enabled the Company to extend its cash horizon by around 3 months. At the same time, in addition to reducing its expenses, the Company is negotiating with its various stakeholders and seeking the agreement necessary to secure its financial and cash trajectory over the next twelve months.

4. GOVERNANCE

The Annual General Meeting of June 4, 2024 reappointed Mrs. Shefali Agarwal and Mr. Bryan Giraud as directors for a three-year term.

At a meeting held on November 13, 2024, the Board of Directors of Valerio Therapeutics decided to appoint Mr. Julien Miara as Chief Executive Officer and Chairman of the Board of Directors of Valerio Therapeutics, succeeding Mrs. Shefali Agarwal.

At a meeting held on November 20, 2024, the Board of Directors of Valerio Therapeutics acknowledged the resignation of Mr. Robert L Coleman from his directorship.

At a meeting held on November 21, 2024, the Board of Directors of Valerio Therapeutics decided to appoint Mr. Antoine Barouky as Chief Operating Officer of Valerio Therapeutics.

On February 20, 2025, the Board of Directors decided to separate the functions of Chairman of the Board and Chief Executive Officer. GammaX Corporate Advisory has resigned and M. Jacques Mallet

has been appointed Chairman of the Board of Directors. Mr. Julien Miara was confirmed as Chief Executive Officer of the Company. Mr Khalil Barrage has resigned as a director of the Company, and Mr Antoine Barouky, currently Chief Operating Officer, has been co-opted as a director of the Company.

5. CHRONOLOGICAL SUMMARY OF COMPANY PRESS RELEASES FOR FISCAL YEAR 2024

The full text of press releases can be consulted on the Company's website (www.valeriotx.com).

January 25,2024	Half-yearly report on Valerio Therapeutics' liquidity contract
February 5, 2024	Valerio Therapeutics announces a loss-driven capital reduction through a reduction in the par value of the company's shares
April 30, 2024	Publication of 2023 annual report
May 22, 2024	Valerio Therapeutics provides clinical development update on its phase 1/2 clinical trial VIO-01
September 29, 2024	Half-yearly report on liquidity contract with Kepler Cheuvreux
September 30, 2024	Valerio Therapeutics announces first-half 2024 financial results and business review
September 30, 2024	Valerio Therapeutics acquires Emglev Therapeutics, a company specializing in single-domain antibody therapies
November 15, 2024	Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024

6. SIGNIFICANT EVENTS AFTER DECEMBER 31, 2024

On February 3, 2025, the Company announced its strategic decision to discontinue all clinical trials and related activities, including the ongoing VIO-01 trial. This decision was taken by the Board of Directors in view of the challenge posed by the Company's financing. The end of clinical trials will enable the company to focus exclusively on early-stage drug development, ensuring efficient use of available capital while maintaining a strong focus on innovation. As part of this transition, the Company will cease its oncology clinical phase activities and close its US office in Lexington, MA.

On February 27, 2025, the Company announced that it had terminated the liquidity contract entered into on October 29, 2018 with KEPLER CHEUVREUX. The termination took effect on February 19, 2025. This termination was decided as part of the savings made by the Company given its cash position. The Company has no plans to enter into another liquidity contract at this stage.

TERMS OF PARTICIPATION IN THE GENERAL MEETING

All shareholders, regardless of the number of shares they own, are entitled to attend the meeting.

Justification of the right to participate in the General Meeting

The right to attend the meeting is evidenced by the registration of the shares in the name of the shareholder or of the intermediary registered on the shareholder's behalf, on **April 7, 2025, at 00:00** Paris time, either in the registered share accounts held by Société Générale, or in the bearer share accounts held by an authorized intermediary.

The registration of shares in bearer share accounts held by an authorized intermediary is evidenced by a certificate of participation issued by the intermediary, appended to the absentee voting or proxy form or the request for an admission card drawn up in the name of the shareholder or on behalf of the shareholder represented by the registered intermediary. A certificate is also issued to shareholders wishing to attend the meeting in person who have not received their admission card by midnight Paris time on **the second business day** prior to the meeting.

How to attend the meeting

1. Shareholders wishing to attend the meeting in person:
 - Registered shareholders should request an admission card by sending the duly completed postal voting form, using the prepaid envelope enclosed with the notice of meeting, or by post to Société Générale Securities Services (Service Assemblées, CS 30812, 44308 Nantes Cedex 3); if they have not received their admission card by the **second business day** prior to the meeting, they may go directly to the appropriate counter on the day of the meeting, with proof of identity.
 - Holders of bearer shares should ask the authorized intermediary managing their share account to send them an admission card.

2. Shareholders not attending the meeting in person and wishing to vote by post or by proxy
 - For registered shareholders: return the single postal voting form or proxy form, which will be sent with the notice of meeting, either by post using the T envelope enclosed with the notice of meeting to the following address: Société Générale - Service assemblées - 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3, or by e-mail to ag2025@valeriotx.com;
 - For holders of bearer shares: request this form from the intermediary who manages their shares, as from the date on which the meeting is called. The single postal or proxy voting form must be accompanied by a certificate of participation issued by the financial intermediary and returned by the latter by post to the following address Société Générale - Service assemblées - 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3 or by e-mail to ag2025@valeriotx.com.

Requests for voting forms must reach Société Générale **via the shareholder's financial intermediary**, at one of the addresses indicated above, at least six days before the scheduled date of the meeting, i.e. **April 3, 2025**.

Only duly completed voting forms received by Société Générale, at one of the above addresses, at least **four days** before the date of the Meeting, i.e. by **11:59 p.m. on April 5, 2025** at the latest, **and**

accompanied by the certificate of participation issued by the authorized intermediaries, will be taken into account in the case of bearer shares.

Shareholders wishing to appoint a proxy

In accordance with the provisions of Article R. 225-79 of the French Commercial Code, notification of the appointment and revocation of a proxy may be made electronically, as follows:

- For registered shareholders: the shareholder must send an e-mail to the following e-mail address: ag2025@valeriotx.com, specifying his or her surname, first name, address and Société Générale identifier for pure registered shareholders (information available at the top left of the account statement) or his or her identifier with his or her financial intermediary if he or she is an administered registered shareholder, as well as the surname, first name and address of the appointed or revoked proxy;
- For bearer shareholders: the shareholder must send an e-mail to the following address: ag2025@valeriotx.com, specifying his or her surname, first name, address and bank details, as well as the surname, first name and address of the appointed or revoked proxy. **The shareholder must then ask the financial intermediary managing his or her securities account to send written confirmation to Société Générale, Services Assemblées, 32 rue du Champ de Tir, CS 30812, 44308 Nantes cedex 3.**

In order for duly signed and completed proxy designations or revocations to be validly taken into account, they must reach the Company or Société Générale no later than **four days** before the date of the Meeting, i.e. **by 11:59 p.m. on April 5, 2025** at the latest, regardless of whether notifications are made electronically or by post.

Any shareholder who has already cast a vote, sent a proxy or requested an admission card or certificate of attendance :

- can no longer choose another method of participation;
- may sell all or part of its shares at any time. If the sale takes place before **April 7, 2025 at midnight**, Paris time, the company will invalidate or amend, as appropriate, the absentee ballot, the proxy, the admission card or the certificate of attendance. To this end, the authorized intermediary holding the shares will notify the Company or its agent of the sale, and provide the necessary information.

Written Questions

Any shareholder may also submit a written question. These questions must be sent:

- to the registered office at 49 Boulevard du Général Martial Valin, 75015 Paris, by registered letter with acknowledgment of receipt, addressed to the Chairman of the Board of Directors,
- to the following email address: ag2025@valeriotx.com,

no later than **four business days** before the General Meeting, i.e., no later than **April 3, 2025**, accompanied by a certificate of registration in either the registered share accounts or the bearer share accounts held by the authorized intermediary.

Shareholders' right to information

In accordance with the law, all documents required to be communicated at general meetings will be made available to shareholders at the registered office within the legal timeframe. These documents will be available for consultation on the Company's website www.valeriotx.com.

The Board of Directors

REQUEST FOR THE SENDING OF ADDITIONAL DOCUMENTS
--

Concerning the Annual General Meeting of April 9, 2025

I, the undersigned : :

NAME :

First name :

Adress :

Owner of _____ registered shares

Owner of _____ bearer shares

Of VALERIO THERAPEUTICS

hereby acknowledge having received the documents relating to the above-mentioned General Meeting and referred to in Article R.225-81 of the French Commercial Code,

request that the documents and information concerning the Annual General Meeting of April 9, 2025, as referred to in Article R.225-83 of the French Commercial Code, be sent to me.

_____, _____ 2025.

Signature

* In accordance with article R. 225-88 paragraph 3 of the French Commercial Code, holders of registered shares may, by means of a single request, obtain from the Company the documents and information referred to in articles R. 225-81 and R. 225-83 of the French Commercial Code, on the occasion of each subsequent General Meeting. Should a shareholder wish to take advantage of this option, he or she must indicate this on the request form.